#Biotech #Bourse Five Companies Likely To Bid For Onyx Pharma - TheStreet http://t.co/jB64YZxKja cc @GHABAULT @ALarigaudrieBFM @jlreynal
July 01, 2013
Publicité
/http%3A%2F%2Fi.thestreet.com%2Ffiles%2Ftsc%2Fv2008%2Fphotos%2Fall-pics%2F101612_biotech1_lead.jpg)
Five Companies Likely To Bid For Onyx Pharma
SOUTH SAN FRANCISCO ( TheStreet) -- Onyx Pharmaceuticals has rejected Amgen's takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company's most important asset -- the blood cancer drug Kyprolis.